Illumina
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Trade Illumina 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About ILMN
Illumina, Inc. engages in the development, manufacturing, and marketing of life science tools and integrated systems for large-scale analysis of genetic variation and function. It operates through the Core Illumina segment, which serves customers in the research, clinical and applied markets fields, and enables the adoption of a variety of genomic solutions.
CEOJacob Thaysen
CEOJacob Thaysen
Employees10,370
Employees10,370
HeadquartersSan Diego, California
HeadquartersSan Diego, California
Founded1998
Founded1998
Employees10,370
Employees10,370
ILMN Key Statistics
Market cap15.51B
Market cap15.51B
Price-Earnings ratio12.93
Price-Earnings ratio12.93
Dividend yield—
Dividend yield—
Average volume1.75M
Average volume1.75M
High today$102.68
High today$102.68
Low today$100.68
Low today$100.68
Open price$101.98
Open price$101.98
Volume829.12K
Volume829.12K
52 Week high$156.66
52 Week high$156.66
52 Week low$68.70
52 Week low$68.70
ILMN News
Simply Wall St 3d
Illumina Is Up 7.7% After Launching AI-Focused BioInsight Unit for Drug Discovery InnovationOn October 1, 2025, Illumina, Inc. launched BioInsight, a new business unit focused on integrating artificial intelligence, sequencing, and software to accelera...
TipRanks 4d
Illumina price target raised to $95 from $90 at BarclaysBarclays raised the firm’s price target on Illumina (ILMN) to $95 from $90 and keeps an Underweight rating on the shares as part of a Q3 preview for the life sc...
Analyst ratings
48%
of 23 ratingsBuy
39.1%
Hold
47.8%
Sell
13%
People also own
Based on the portfolios of people who own ILMN. This list is generated using Robinhood data, and it’s not a recommendation.